$KITE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Kite Pharma, Inc.. Get notifications about new insider transactions in Kite Pharma, Inc. for free.
Page: < prev 1 2 3 4 5 6 7 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Grant | A | 0.00 | 1,950 | 0 | 1,950 | 0 to 2 K |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Grant | A | 0.00 | 1,950 | 0 | 216,950 | 215 K to 217 K (+0.91 %) |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Grant | A | 0.00 | 1,950 | 0 | 1,950 | 0 to 2 K |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Grant | A | 0.00 | 1,950 | 0 | 87,988 | 86 K to 88 K (+2.27 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 1,500 | 10,335 | 83,708 | |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 1,500 | 10,335 | 85,208 | |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 51.90 | 175 | 9,083 | 14,867 | 15 K to 14.9 K (-1.16 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 51.22 | 1,325 | 67,867 | 15,042 | 16.4 K to 15 K (-8.10 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 1,500 | 10,335 | 16,367 | 14.9 K to 16.4 K (+10.09 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 50.00 | 1,500 | 75,000 | 14,867 | 16.4 K to 14.9 K (-9.16 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 1,500 | 10,335 | 16,367 | 14.9 K to 16.4 K (+10.09 %) |
| May 18 2016 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Option Exercise | A | 45.04 | 125,000 | 5,630,000 | 125,000 | |
| Apr 06 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 305,394 | |
| Apr 06 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 50.00 | 10,000 | 500,000 | 95,401 | 105.4 K to 95.4 K (-9.49 %) |
| Apr 06 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 105,401 | 95.4 K to 105.4 K (+10.48 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 7,292 | 50,242 | 86,708 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 1,708 | 11,768 | 14,292 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 47.82 | 259 | 12,385 | 14,867 | 15.1 K to 14.9 K (-1.71 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 46.49 | 461 | 21,432 | 15,126 | 15.6 K to 15.1 K (-2.96 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 45.32 | 1,538 | 69,702 | 15,587 | 17.1 K to 15.6 K (-8.98 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 44.56 | 6,742 | 300,424 | 17,125 | 23.9 K to 17.1 K (-28.25 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 9,000 | 62,010 | 23,867 | 14.9 K to 23.9 K (+60.54 %) |
| Mar 24 2016 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Grant | A | 0.00 | 2,071 | 0 | 2,071 | 0 to 2.1 K |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 1,006 | 17,102 | 30,575 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 7,500 | 5,250 | 56,250 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 47.78 | 255 | 12,184 | 10,655 | 10.9 K to 10.7 K (-2.34 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 46.34 | 436 | 20,204 | 10,910 | 11.3 K to 10.9 K (-3.84 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 45.09 | 7,815 | 352,378 | 11,346 | 19.2 K to 11.3 K (-40.79 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 1,006 | 17,102 | 19,161 | 18.2 K to 19.2 K (+5.54 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 7,500 | 5,250 | 18,155 | 10.7 K to 18.2 K (+70.39 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 8,500 | 11,475 | 95,830 | |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 48.07 | 189 | 9,085 | 10,211 | 10.4 K to 10.2 K (-1.82 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 46.55 | 499 | 23,228 | 10,400 | 10.9 K to 10.4 K (-4.58 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 45.12 | 7,812 | 352,477 | 10,899 | 18.7 K to 10.9 K (-41.75 %) |
| Mar 17 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 8,500 | 11,475 | 18,711 | 10.2 K to 18.7 K (+83.24 %) |
| Mar 16 2016 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | A | 44.91 | 75,000 | 3,368,250 | 75,000 | |
| Mar 16 2016 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | A | 44.91 | 155,000 | 6,961,050 | 155,000 | |
| Mar 16 2016 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
| Mar 03 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 315,394 | |
| Mar 03 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 50.03 | 10,000 | 500,300 | 95,401 | 105.4 K to 95.4 K (-9.49 %) |
| Mar 03 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 105,401 | 95.4 K to 105.4 K (+10.48 %) |
| Feb 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 9,632 | 6,742 | 62,743 | |
| Feb 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 46.01 | 100 | 4,601 | 9,098 | 9.2 K to 9.1 K (-1.09 %) |
| Feb 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 45.05 | 9,532 | 429,417 | 9,198 | 18.7 K to 9.2 K (-50.89 %) |
| Feb 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 9,632 | 6,742 | 18,730 | 9.1 K to 18.7 K (+105.87 %) |
| Feb 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 104,330 | |
| Feb 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 46.01 | 100 | 4,601 | 8,741 | 8.8 K to 8.7 K (-1.13 %) |
| Feb 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 45.07 | 9,467 | 426,678 | 8,841 | 18.3 K to 8.8 K (-51.71 %) |
| Feb 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 18,308 | 8.7 K to 18.3 K (+109.45 %) |
| Feb 18 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 16,000 | |
| Feb 18 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | A | 6.89 | 25,000 | 172,250 | 25,000 | |
| Feb 18 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 44.47 | 1,388 | 61,724 | 13,742 | 15.1 K to 13.7 K (-9.17 %) |
| Feb 18 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 44.00 | 7,612 | 334,928 | 15,130 | 22.7 K to 15.1 K (-33.47 %) |
| Feb 18 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 9,000 | 62,010 | 22,742 | 13.7 K to 22.7 K (+65.49 %) |
| Feb 16 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 18,750 | 13,125 | 72,375 | |
| Feb 16 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 64.16 | 18,750 | 1,202,964 | 9,098 | 27.8 K to 9.1 K (-67.33 %) |
| Feb 16 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 18,750 | 13,125 | 27,848 | 9.1 K to 27.8 K (+206.09 %) |
| Feb 04 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 1,900 | 2,565 | 325,394 | |
| Feb 04 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 50.13 | 1,900 | 95,247 | 94,007 | 95.9 K to 94 K (-1.98 %) |
| Feb 04 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 1,900 | 2,565 | 95,907 | 94 K to 95.9 K (+2.02 %) |
| Feb 03 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 60,000 | |
| Feb 03 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 49.20 | 153 | 7,528 | 7,688 | 7.8 K to 7.7 K (-1.95 %) |
| Feb 03 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 48.47 | 1,410 | 68,343 | 7,841 | 9.3 K to 7.8 K (-15.24 %) |
| Feb 03 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 47.38 | 4,938 | 233,962 | 9,251 | 14.2 K to 9.3 K (-34.80 %) |
| Feb 03 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 46.50 | 2,499 | 116,204 | 14,189 | 16.7 K to 14.2 K (-14.97 %) |
| Feb 03 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 16,688 | 7.7 K to 16.7 K (+117.07 %) |
| Jan 29 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 8,100 | 10,935 | 327,294 | |
| Jan 29 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 53.12 | 100 | 5,312 | 94,007 | 94.1 K to 94 K (-0.11 %) |
| Jan 29 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 52.91 | 2,800 | 148,148 | 94,107 | 96.9 K to 94.1 K (-2.89 %) |
| Jan 29 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 51.34 | 2,700 | 138,618 | 96,907 | 99.6 K to 96.9 K (-2.71 %) |
| Jan 29 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 50.42 | 2,500 | 126,050 | 99,607 | 102.1 K to 99.6 K (-2.45 %) |
| Jan 29 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 8,100 | 10,935 | 102,107 | 94 K to 102.1 K (+8.62 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 94,000 | |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 57.75 | 200 | 11,550 | 13,742 | 13.9 K to 13.7 K (-1.43 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 57.11 | 648 | 37,007 | 13,942 | 14.6 K to 13.9 K (-4.44 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 55.98 | 1,121 | 62,754 | 14,590 | 15.7 K to 14.6 K (-7.14 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 55.17 | 5,987 | 330,303 | 15,711 | 21.7 K to 15.7 K (-27.59 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 53.87 | 670 | 36,093 | 21,698 | 22.4 K to 21.7 K (-3.00 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 52.60 | 374 | 19,672 | 22,368 | 22.7 K to 22.4 K (-1.64 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 9,000 | 62,010 | 22,742 | 13.7 K to 22.7 K (+65.49 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 2,767 | 3,735 | 113,897 | |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 6,800 | 9,180 | 116,664 | |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 58.92 | 198 | 11,666 | 8,741 | 8.9 K to 8.7 K (-2.22 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 57.74 | 852 | 49,194 | 8,939 | 9.8 K to 8.9 K (-8.70 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 56.70 | 230 | 13,041 | 9,791 | 10 K to 9.8 K (-2.30 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 55.67 | 635 | 35,350 | 10,021 | 10.7 K to 10 K (-5.96 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 54.58 | 355 | 19,376 | 10,656 | 11 K to 10.7 K (-3.22 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 53.55 | 497 | 26,614 | 11,011 | 11.5 K to 11 K (-4.32 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 2,767 | 3,735 | 11,508 | 8.7 K to 11.5 K (+31.66 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 57.09 | 800 | 45,672 | 8,741 | 9.5 K to 8.7 K (-8.38 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 55.60 | 1,918 | 106,641 | 9,541 | 11.5 K to 9.5 K (-16.74 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 55.07 | 3,166 | 174,352 | 11,459 | 14.6 K to 11.5 K (-21.65 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 53.89 | 645 | 34,759 | 14,625 | 15.3 K to 14.6 K (-4.22 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 52.27 | 271 | 14,165 | 15,270 | 15.5 K to 15.3 K (-1.74 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 6,800 | 9,180 | 15,541 | 8.7 K to 15.5 K (+77.79 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 645 | 10,965 | 32,588 | |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 5,500 | 3,850 | 91,125 | |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 57.73 | 200 | 11,546 | 9,098 | 9.3 K to 9.1 K (-2.15 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 56.90 | 400 | 22,760 | 9,298 | 9.7 K to 9.3 K (-4.12 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 55.83 | 1,054 | 58,845 | 9,698 | 10.8 K to 9.7 K (-9.80 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 55.16 | 3,527 | 194,549 | 10,752 | 14.3 K to 10.8 K (-24.70 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 53.95 | 700 | 37,765 | 14,279 | 15 K to 14.3 K (-4.67 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 52.49 | 264 | 13,857 | 14,979 | 15.2 K to 15 K (-1.73 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 645 | 10,965 | 15,243 | 14.6 K to 15.2 K (+4.42 %) |
| Jan 19 2016 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 5,500 | 3,850 | 14,598 | 9.1 K to 14.6 K (+60.45 %) |
| Jan 05 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 69,000 | |
| Jan 05 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 62.44 | 110 | 6,868 | 7,688 | 7.8 K to 7.7 K (-1.41 %) |
| Jan 05 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 61.66 | 6,719 | 414,294 | 7,798 | 14.5 K to 7.8 K (-46.28 %) |
| Jan 05 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 61.09 | 2,171 | 132,626 | 14,517 | 16.7 K to 14.5 K (-13.01 %) |
| Jan 05 2016 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 16,688 | 7.7 K to 16.7 K (+117.07 %) |
| Dec 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 335,394 | |
| Dec 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 61.99 | 2,710 | 167,993 | 94,007 | 96.7 K to 94 K (-2.80 %) |
| Dec 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 61.40 | 7,290 | 447,606 | 96,717 | 104 K to 96.7 K (-7.01 %) |
| Dec 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 104,007 | 94 K to 104 K (+10.64 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Option Exercise | A | 63.87 | 160,000 | 10,219,200 | 160,000 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Grant | A | 0.00 | 44,000 | 0 | 54,000 | 10 K to 54 K (+440.00 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | A | 63.87 | 8,800 | 562,056 | 8,800 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Grant | A | 0.00 | 5,800 | 0 | 7,688 | 1.9 K to 7.7 K (+307.20 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | A | 63.87 | 8,800 | 562,056 | 8,800 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Grant | A | 0.00 | 5,800 | 0 | 8,741 | 2.9 K to 8.7 K (+197.21 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | A | 63.87 | 24,800 | 1,583,976 | 24,800 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Grant | A | 0.00 | 6,900 | 0 | 9,098 | 2.2 K to 9.1 K (+313.92 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | A | 63.87 | 26,400 | 1,686,168 | 26,400 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Grant | A | 0.00 | 7,400 | 0 | 13,742 | 6.3 K to 13.7 K (+116.68 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | A | 63.87 | 33,000 | 2,107,710 | 33,000 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Grant | A | 0.00 | 9,200 | 0 | 9,200 | 0 to 9.2 K |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | A | 63.87 | 66,100 | 4,221,807 | 66,100 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Grant | A | 0.00 | 18,500 | 0 | 25,404 | 6.9 K to 25.4 K (+267.96 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | A | 63.87 | 66,100 | 4,221,807 | 66,100 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Grant | A | 0.00 | 18,500 | 0 | 94,007 | 75.5 K to 94 K (+24.50 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | A | 63.87 | 100,700 | 6,431,709 | 100,700 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Grant | A | 0.00 | 28,200 | 0 | 28,200 | 0 to 28.2 K |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 103,000 | |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 65.27 | 491 | 32,048 | 6,342 | 6.8 K to 6.3 K (-7.19 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 64.58 | 3,488 | 225,255 | 6,833 | 10.3 K to 6.8 K (-33.80 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 63.59 | 2,285 | 145,303 | 10,321 | 12.6 K to 10.3 K (-18.13 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 62.64 | 2,736 | 171,383 | 12,606 | 15.3 K to 12.6 K (-17.83 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 9,000 | 62,010 | 15,342 | 6.3 K to 15.3 K (+141.91 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 645 | 10,965 | 33,233 | |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 5,500 | 3,850 | 96,625 | |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 64.97 | 1,145 | 74,391 | 2,198 | 3.3 K to 2.2 K (-34.25 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 64.27 | 2,400 | 154,248 | 3,343 | 5.7 K to 3.3 K (-41.79 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 62.76 | 2,600 | 163,176 | 5,743 | 8.3 K to 5.7 K (-31.16 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 645 | 10,965 | 8,343 | 7.7 K to 8.3 K (+8.38 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 5,500 | 3,850 | 7,698 | 2.2 K to 7.7 K (+250.23 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 123,464 |